Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy
- 1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo 315211, China
- 2Department of Thoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China
Abstract
Non-coding RNAs (ncRNAs) regulate antitumor immunity but clinical use is hindered by instability, poor specificity, and immunogenic risk. Lipid nanoparticles (LNPs) offer a promising delivery solution due to biocompatibility, a modifiable surface, and efficient ncRNA encapsulation. Preclinical and early clinical studies have demonstrated the efficacy of LNP-ncRNA therapies in various cancers, including respiratory, digestive, and neurologic malignancies, and in cancer immunotherapy. This review evaluates engineered LNPs administered via different routes, explains the mechanisms that promote antitumor effects, and highlights advances in overcoming delivery barriers to enhance immunotherapy. Current limitations of engineered LNPs are also analyzed, essential translational challenges are identified, and future directions to facilitate the clinical application of LNP-based ncRNA therapies are suggested.
Related
- Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy
- Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles.
- Targeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy.
- Ultrasound-Triggered piRNA Delivery Using Biomimetic Phase-Changeable Nanoparticles for Theranostics of Myocardial Infarction.
- Engineering morphology of tetrasulfide-incorporated mesoporous silica nanoparticles for enhanced mRNA delivery
BibTeX
@article{sheng2026noncoding,
title = {{Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy}},
author = {Yufei Sheng and Lulu Yang and Boyang Wang and Wentao Hu and Chengwei Zhou and Zhaohui Gong},
journal = {Cancer Biology \& Medicine},
year = {2026},
month = oct,
doi = {10.20892/j.issn.2095-3941.2025.0825},
url = {https://doi.org/10.20892/j.issn.2095-3941.2025.0825},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy
AU - Yufei Sheng
AU - Lulu Yang
AU - Boyang Wang
AU - Wentao Hu
AU - Chengwei Zhou
AU - Zhaohui Gong
PY - 2026
DA - 2026/10/01
JO - Cancer Biology & Medicine
DO - 10.20892/j.issn.2095-3941.2025.0825
UR - https://doi.org/10.20892/j.issn.2095-3941.2025.0825
AB - Non-coding RNAs (ncRNAs) regulate antitumor immunity but clinical use is hindered by instability, poor specificity, and immunogenic risk. Lipid nanoparticles (LNPs) offer a promising delivery solution due to biocompatibility, a modifiable surface, and efficient ncRNA encapsulation. Preclinical and early clinical studies have demonstrated the efficacy of LNP-ncRNA therapies in various cancers, including respiratory, digestive, and neurologic malignancies, and in cancer immunotherapy. This review evaluates engineered LNPs administered via different routes, explains the mechanisms that promote antitumor effects, and highlights advances in overcoming delivery barriers to enhance immunotherapy. Current limitations of engineered LNPs are also analyzed, essential translational challenges are identified, and future directions to facilitate the clinical application of LNP-based ncRNA therapies are suggested.
SN - 2095-3941
ER -